Home Cart Sign in  
Chemical Structure| 85386-14-7 Chemical Structure| 85386-14-7

Structure of 85386-14-7

Chemical Structure| 85386-14-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 85386-14-7 ]

CAS No. :85386-14-7
Formula : C13H12N2O2
M.W : 228.25
SMILES Code : O=C(C1=CN=C(C2=CC=CC=C2)N=C1)OCC
MDL No. :MFCD09863207
InChI Key :ADXNMWBLJLAMNG-UHFFFAOYSA-N
Pubchem ID :10489528

Safety of [ 85386-14-7 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 85386-14-7 ] Show Less

Physicochemical Properties

Num. heavy atoms 17
Num. arom. heavy atoms 12
Fraction Csp3 0.15
Num. rotatable bonds 4
Num. H-bond acceptors 4.0
Num. H-bond donors 0.0
Molar Refractivity 63.55
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

52.08 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.63
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.08
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.32
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.7
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.68
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.28

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.82
Solubility 0.342 mg/ml ; 0.0015 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.8
Solubility 0.359 mg/ml ; 0.00157 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.66
Solubility 0.00502 mg/ml ; 0.000022 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

Yes
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.22 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.81

Application In Synthesis of [ 85386-14-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 85386-14-7 ]
  • Downstream synthetic route of [ 85386-14-7 ]

[ 85386-14-7 ] Synthesis Path-Upstream   1~18

  • 1
  • [ 24755-82-6 ]
  • [ 85386-14-7 ]
YieldReaction ConditionsOperation in experiment
50%
Stage #1: With zinc In tetrahydrofuran at 60℃; for 1 h;
Stage #2: With acetic acid In tetrahydrofuran at 60℃; for 23 h;
In a round bottomed flask under argon atmosphere were successively added anhydrous ethanol(5 mL), sodium metal (0.426 g, 18.5 mmol), benzamidine hydrochloride (2.90 g, 18.5 mmol)and diethyl 2-(ethoxymethylene)malonate (4.0 g, 18.5 mmol). The reaction mixture was stirredat room temperature for 9 h, and then poured into ice. The precipitate was filtered, washedwith coldwater and recrystallized in EtOH-MeOH-CHCl3 (1:1:1) (45 mL), giving the ethyl4-hydroxy-2-phenylpyrimidine-5-carboxylate (8) as a white crystalline solid in 50percent yield. Thederivative 8 (1.2 g, 4.91 mmol) and POCl3 (9.8 g, 63.9 mmol) were refluxed at 100oC for 1 h. Theexcess of POCl3 was removed under vacuum, ice was added on the resulting solid into the reactionflask, followed by filtration and washing with cold water. The chloride compound 9, obtained as awhite amorphous solid in 98percent yield, was successively dehalogenated with zinc powder (0.176 g,2.69 mmol, 4 equiv) in anhydrous THF (2 mL). The reaction mixture was stirred at 60 °C for 1 h, andthen 5 drops of acetic acid were added to the reaction vessel. After stirring at 60 °C for 23 h, thereaction mixture was cooled to room temperature, followed by addition of CH2Cl2 (3 mL), filtrationand evaporation of solvent. Purification by silica gel column chromatography (n-hexane-EtOAc 0.6percent)afforded the title compound as a white crystalline solid in 50percent yield.
References: [1] Molecules, 2013, vol. 18, # 10, p. 11683 - 11704.
[2] Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation), 1983, vol. 32, # 2, p. 265 - 270[3] Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya, 1983, # 2, p. 299 - 304.
  • 2
  • [ 89793-12-4 ]
  • [ 98-80-6 ]
  • [ 85386-14-7 ]
YieldReaction ConditionsOperation in experiment
65% With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate In 1,4-dioxane at 100℃; General procedure: To a solution of and halide in the indicated solvent is added boronic acid or ester, carbonate base, and palladium catalyst at room temperature. After stirring at 100 °C overnight, the mixture is cooled and concentrated.Following Procedure B using ii (500 mg, 2.67 mrnol). dioxane (10 mL), phenylboronic acid (650 mg, 5.36 mmoi), potassium carbonate (1.85 g. 13.4 mmol), and Pd(dppf)C12 (50 mg), then purified by silica gel column chromatography (EA:PE = 1:100 to 1:50) to give 20 as a white solid (400 mg, 65percent yield). (MS: M+Hi 229.1)
References: [1] Patent: WO2017/176812, 2017, A1, . Location in patent: Paragraph 0215; 0248.
  • 3
  • [ 1670-14-0 ]
  • [ 92385-43-8 ]
  • [ 85386-14-7 ]
YieldReaction ConditionsOperation in experiment
75% With sodium In ethanol Example 32
2-PHENYLPYRIMIDINE-5-CARBONYL CHLORIDE
A solution of ethyl 3-N,N-dimethylamino-2-formylacrylate (4.0 g, 23 mmol) (Arnold, Coll. Czech. Chem. Commun. 26:3051, 1961), benzamidine hydrochloride (4.0 g, 26 mmol) and sodium (0.65 g, 28 mmol) in EtOH (40 mL) was heated at reflux for 1 h.
The solution was filtered and concentrated and the residue partitioned between EtOAc and dilute HCl (10percent).
The organic layer was dried (Na2 SO4), and concentrated to give ethyl 2-phenylpyrimidine-5-carboxylate (4.0 g, 75percent yield); m.p. >220° C. (dec.).
References: [1] Journal of medicinal chemistry, 2000, vol. 43, # 21, p. 3995 - 4004.
[2] Patent: US5811428, 1998, A, .
  • 4
  • [ 80370-42-9 ]
  • [ 1670-14-0 ]
  • [ 85386-14-7 ]
References: [1] European Journal of Medicinal Chemistry, 2017, vol. 137, p. 96 - 107.
  • 5
  • [ 64-17-5 ]
  • [ 122773-94-8 ]
  • [ 85386-14-7 ]
  • [ 122773-96-0 ]
References: [1] Chemistry of Heterocyclic Compounds (New York, NY, United States), 1993, vol. 29, # 4, p. 432 - 436[2] Khimiya Geterotsiklicheskikh Soedinenii, 1993, # 4, p. 509 - 513.
  • 6
  • [ 122773-94-8 ]
  • [ 85386-14-7 ]
  • [ 122773-96-0 ]
References: [1] Chemistry of Heterocyclic Compounds (New York, NY, United States), 1993, vol. 29, # 4, p. 432 - 436[2] Khimiya Geterotsiklicheskikh Soedinenii, 1993, # 4, p. 509 - 513.
  • 7
  • [ 623-47-2 ]
  • [ 85386-14-7 ]
References: [1] Journal of Organic Chemistry, 1996, vol. 61, # 7, p. 2470 - 2483.
  • 8
  • [ 77232-48-5 ]
  • [ 85386-14-7 ]
References: [1] Chemistry of Heterocyclic Compounds (New York, NY, United States), 1988, p. 303 - 307[2] Khimiya Geterotsiklicheskikh Soedinenii, 1988, vol. 24, # 3, p. 371 - 375.
[3] Chemistry of Heterocyclic Compounds (New York, NY, United States), 1988, p. 303 - 307[4] Khimiya Geterotsiklicheskikh Soedinenii, 1988, vol. 24, # 3, p. 371 - 375.
  • 9
  • [ 97430-37-0 ]
  • [ 618-39-3 ]
  • [ 85386-14-7 ]
References: [1] Journal of Heterocyclic Chemistry, 1990, vol. 27, # 2, p. 295 - 305.
  • 10
  • [ 64-17-5 ]
  • [ 85386-15-8 ]
  • [ 85386-14-7 ]
References: [1] Chemistry of Heterocyclic Compounds (New York, NY, United States), 1988, p. 303 - 307[2] Khimiya Geterotsiklicheskikh Soedinenii, 1988, vol. 24, # 3, p. 371 - 375.
  • 11
  • [ 1670-14-0 ]
  • [ 85386-14-7 ]
References: [1] Journal of Organic Chemistry, 1996, vol. 61, # 7, p. 2470 - 2483.
  • 12
  • [ 87-13-8 ]
  • [ 85386-14-7 ]
References: [1] Molecules, 2013, vol. 18, # 10, p. 11683 - 11704.
  • 13
  • [ 55613-22-4 ]
  • [ 85386-14-7 ]
References: [1] Molecules, 2013, vol. 18, # 10, p. 11683 - 11704.
  • 14
  • [ 122773-97-1 ]
  • [ 85386-14-7 ]
References: [1] Chemistry of Heterocyclic Compounds (New York, NY, United States), 1988, p. 303 - 307[2] Khimiya Geterotsiklicheskikh Soedinenii, 1988, vol. 24, # 3, p. 371 - 375.
  • 15
  • [ 122774-00-9 ]
  • [ 85386-14-7 ]
References: [1] Chemistry of Heterocyclic Compounds (New York, NY, United States), 1988, p. 303 - 307[2] Khimiya Geterotsiklicheskikh Soedinenii, 1988, vol. 24, # 3, p. 371 - 375.
  • 16
  • [ 64-17-5 ]
  • [ 122773-97-1 ]
  • [ 85386-14-7 ]
References: [1] Chemistry of Heterocyclic Compounds (New York, NY, United States), 1988, p. 303 - 307[2] Khimiya Geterotsiklicheskikh Soedinenii, 1988, vol. 24, # 3, p. 371 - 375.
  • 17
  • [ 176240-36-1 ]
  • [ 85386-14-7 ]
References: [1] Journal of Organic Chemistry, 1996, vol. 61, # 7, p. 2470 - 2483.
  • 18
  • [ 122773-96-0 ]
  • [ 85386-14-7 ]
References: [1] Chemistry of Heterocyclic Compounds (New York, NY, United States), 1988, p. 303 - 307[2] Khimiya Geterotsiklicheskikh Soedinenii, 1988, vol. 24, # 3, p. 371 - 375.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 85386-14-7 ]

Aryls

Chemical Structure| 1088994-22-2

A133786 [1088994-22-2]

5-Methyl-2-(pyrimidin-2-yl)benzoicacid

Similarity: 0.81

Chemical Structure| 579476-26-9

A152689 [579476-26-9]

3-Pyrimidin-2-yl-benzoic acid

Similarity: 0.81

Chemical Structure| 199678-12-1

A332028 [199678-12-1]

4-Pyrimidin-2-yl-benzoic acid

Similarity: 0.81

Chemical Structure| 127958-10-5

A102650 [127958-10-5]

2-Methyl-4-phenylpyrimidine-5-carboxylic acid

Similarity: 0.73

Chemical Structure| 144501-28-0

A944510 [144501-28-0]

Ethyl 2-Phenylpyridine-3-carboxylate

Similarity: 0.70

Esters

Chemical Structure| 2134-38-5

A182923 [2134-38-5]

Ethyl 2-methylpyrimidine-5-carboxylate

Similarity: 0.78

Chemical Structure| 65195-35-9

A118296 [65195-35-9]

Ethyl 4-aminopyrimidine-5-carboxylate

Similarity: 0.76

Chemical Structure| 75353-50-3

A131318 [75353-50-3]

Methyl 2-aminoquinoline-3-carboxylate

Similarity: 0.76

Chemical Structure| 50741-46-3

A210849 [50741-46-3]

Ethyl quinoline-3-carboxylate

Similarity: 0.74

Chemical Structure| 71406-78-5

A132737 [71406-78-5]

Ethyl 4-amino-2-chloropyrimidine-5-carboxylate

Similarity: 0.72

Related Parent Nucleus of
[ 85386-14-7 ]

Pyrimidines

Chemical Structure| 1088994-22-2

A133786 [1088994-22-2]

5-Methyl-2-(pyrimidin-2-yl)benzoicacid

Similarity: 0.81

Chemical Structure| 579476-26-9

A152689 [579476-26-9]

3-Pyrimidin-2-yl-benzoic acid

Similarity: 0.81

Chemical Structure| 199678-12-1

A332028 [199678-12-1]

4-Pyrimidin-2-yl-benzoic acid

Similarity: 0.81

Chemical Structure| 2134-38-5

A182923 [2134-38-5]

Ethyl 2-methylpyrimidine-5-carboxylate

Similarity: 0.78

Chemical Structure| 65195-35-9

A118296 [65195-35-9]

Ethyl 4-aminopyrimidine-5-carboxylate

Similarity: 0.76